Sibutramine Cardiovascular Morbidity/Mortality Outcomes Study in Overweight or Obese Subjects at Risk of a Cardiovascular Event.

Trial Profile

Sibutramine Cardiovascular Morbidity/Mortality Outcomes Study in Overweight or Obese Subjects at Risk of a Cardiovascular Event.

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Jun 2012

At a glance

  • Drugs Sibutramine (Primary)
  • Indications Obesity; Overweight
  • Focus Adverse reactions; Pharmacodynamics; Registrational; Therapeutic Use
  • Acronyms SCOUT
  • Sponsors Abbott Laboratories
  • Most Recent Events

    • 12 May 2012 Results presented at the 19th European Congress on Obesity.
    • 08 Oct 2010 Based primarily on the results of this trial, Abbott will voluntarily withdraw sibutramine from the Canadian market.
    • 08 Oct 2010 Based primarily on the results of this trial, Abbott will voluntarily withdraw sibutramine from the US market at the request of the US FDA.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top